Amarin Corp Plc (AMRN)

[Sam81]

Oppenheimer Update;

https://drive.google.com/file/d/0B1gB2YESBJV7MDAzc0ZmVUNiakk/view


Vascepa is slowly but surely becoming a real drug in the CV space, and we would not be surprised to see pharma interest at some point. However, it seems less clear whether or not a buyer would pay up for REDUCEIT optionality, which doesn't read out until 1H18.

Upcoming catalysts include
1)completion of REDUCE-IT enrollment by year end 2015 or early 2016;
2)Vascepa script growth in the near/medium term as promotional efforts increase following favorable First Amendment ruling;
3)interim analysis of REDUCE-IT data in 2016.

KEY RISKS
Note: We view AMRN, as a stock trading under $5, as speculative and appropriate for risk-tolerant investors